Koenraad Blot
No más puestos en curso
Perfil
Koenraad Blot worked as an Executive Director of Clinical Research at Theratechnologies, Inc., Head of Medical Affairs and Clinical Operations at Pfizer Inc., and Chief Medical Officer at TiGenix NV and elbion NV.
He holds a doctorate from Ghent University and an undergraduate degree from the University of Antwerp.
Antiguos cargos conocidos de Koenraad Blot.
| Empresas | Cargo | Fin |
|---|---|---|
| TIGENIX NV | Director Técnico/Científico/I+D | - |
| THERATECHNOLOGIES INC. | Director Técnico/Científico/I+D | - |
| PFIZER, INC. | Director Técnico/Científico/I+D | - |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Director Técnico/Científico/I+D | - |
Formación de Koenraad Blot.
| Ghent University | Doctorate Degree |
| University of Antwerp | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
- Bolsa de valores
- Insiders
- Koenraad Blot
